Compare Panacea Biotech with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs STRIDES PHARMA SCIENCE - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH STRIDES PHARMA SCIENCE PANACEA BIOTECH/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 11.6 14.3 80.9% View Chart
P/BV x 2.8 0.8 328.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
PANACEA BIOTECH/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3641,147 31.7%   
Low Rs129642 20.1%   
Sales per share (Unadj.) Rs96.8317.2 30.5%  
Earnings per share (Unadj.) Rs-12.47.8 -158.2%  
Cash flow per share (Unadj.) Rs-2.925.1 -11.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs50.4274.3 18.4%  
Shares outstanding (eoy) m61.2589.50 68.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.52.8 90.4%   
Avg P/E ratio x-19.9114.0 -17.4%  
P/CF ratio (eoy) x-86.435.7 -242.1%  
Price / Book Value ratio x4.93.3 150.0%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m15,10180,058 18.9%   
No. of employees `0002.52.5 98.4%   
Total wages/salary Rs m1,5164,341 34.9%   
Avg. sales/employee Rs Th2,401.911,325.8 21.2%   
Avg. wages/employee Rs Th614.21,731.4 35.5%   
Avg. net profit/employee Rs Th-307.9280.1 -110.0%   
INCOME DATA
Net Sales Rs m5,92828,394 20.9%  
Other income Rs m82941 8.7%   
Total revenues Rs m6,01029,334 20.5%   
Gross profit Rs m8453,965 21.3%  
Depreciation Rs m5851,540 38.0%   
Interest Rs m1,0061,962 51.3%   
Profit before tax Rs m-6641,403 -47.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m2-168 -1.3%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m9997 101.3%   
Profit after tax Rs m-760702 -108.2%  
Gross profit margin %14.314.0 102.1%  
Effective tax rate %-14.96.9 -214.3%   
Net profit margin %-12.82.5 -518.5%  
BALANCE SHEET DATA
Current assets Rs m5,60324,836 22.6%   
Current liabilities Rs m6,91018,993 36.4%   
Net working cap to sales %-22.020.6 -107.1%  
Current ratio x0.81.3 62.0%  
Inventory Days Days20671 290.0%  
Debtors Days Days84113 73.8%  
Net fixed assets Rs m9,94134,289 29.0%   
Share capital Rs m61895 6.8%   
"Free" reserves Rs m3,02623,651 12.8%   
Net worth Rs m3,08724,546 12.6%   
Long term debt Rs m5,70715,513 36.8%   
Total assets Rs m16,07665,437 24.6%  
Interest coverage x0.31.7 19.8%   
Debt to equity ratio x1.80.6 292.5%  
Sales to assets ratio x0.40.4 85.0%   
Return on assets %1.54.1 37.6%  
Return on equity %-24.62.9 -860.7%  
Return on capital %3.96.9 56.8%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60015,697 10.2%   
Fx outflow Rs m1,131735 153.9%   
Net fx Rs m46914,962 3.1%   
CASH FLOW
From Operations Rs m1,1801,871 63.1%  
From Investments Rs m5535,826 9.5%  
From Financial Activity Rs m-1,644-10,157 16.2%  
Net Cashflow Rs m90-2,615 -3.4%  

Share Holding

Indian Promoters % 74.5 27.7 269.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 37.8 1.6%  
FIIs % 1.3 8.6 15.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 25.9 91.1%  
Shareholders   10,259 56,241 18.2%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Telecom Stocks Drag(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is flat while the Hang Seng is down 0.9%.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Oct 23, 2019 10:51 AM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - IPCA LABS COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS